Treatment of autoimmune disease using tolerization in combination with methotrexate
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 10, 1999
Grant Date -
N/A
app pub date -
Jan 23, 1998
filing date -
Jan 23, 1998
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of bystander antigen and methotrexate are effective in combination to suppress autoimmune response associated with the autoimmune disease
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully